Prostate Cancer

TON - September 2013 Vol 6 No 8 published on September 23, 2013 in Noteworthy Numbers, Hematologic Cancers
Wayne Kuznar

As the second leading cause of cancer-related deaths among men in the United States, prostate cancer is expected to cause approximately 29,720 deaths during 2013.1 In recognition of National Prostate Cancer Awareness Month, let’s examine these prostate cancer statistics.

According to the Prostate Cancer Foundation, the average age at the time of prostate cancer diagnosis is 69 years. Moreover, 1
in 14 men between the ages of 60 and 69 years receive a prostate cancer diagnosis.2

Prostate cancer is less common in men younger than 40 years, with 1 in 10,000 men affected.2

Overall, approximately 238,590 men in the US will be diagnosed with prostate cancer in 2013.1

The American Cancer Society states that the ratio of men who will die from prostate cancer is 1:36.1

African American men in the US are almost 2.5 times as likely to die from prostate cancer as white men.3 The rate of prostate cancer is less in Asian American and Hispanic men than in non-Hispanic white men. The reasons behind these racial and ethnic differences are unclear.4

Compared with men in the US whose risk for prostate cancer is 17%, men who live in rural China have less risk (2%) of developing prostate cancer. Yet, the risk for prostate cancer increases for Chinese men if they move to a more western-style culture, reports the Prostate Cancer Foundation.2

According to the World Cancer Research Fund International, about 7 in 10 prostate cancer cases (72%) occur in more developed countries, with the highest rates of diagnosis in Australia and New Zealand, Western Europe, and North America.5

Sources
1. http://www.cancer.org/cancer/prostatecancer/detailed guide/prostate-cancer-key-statistics.
2. http://www.pcf.org/site/c.leJRIROrEpH/b.5802027/k.D271/Prostate_Cancer_Risk_Factors.htm.
3. http://www.pcf.org/site/c.leJRIROrEpH/b.8481037/k.1EF4/AfricanAmerican_Men__Risk_Factors.htm.
4. http://www.cancer.org/cancer/prostatecancer/detailed guide/prostate-cancer-risk-factors.
5. http://www.wcrf.org/cancer_statistics/data_specific_cancers/prostate_cancer_statistics.php.

Related Items
Updated NCCN Treatment Guideline for CML Establishes Criteria for Stopping TKI Therapy
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in NCCN Updates
Immunotherapy Strategies in the Updated NCCN Guideline for NSCLC Hinge on PD-L1 Testing
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in NCCN Updates
Updated NCCN Breast Cancer Guideline Expands Treatment Recommendations for HR-Positive, HER2-Negative Disease
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Breast Cancer, NCCN Updates
Immunotherapy Combination Extends Survival in Advanced Refractory Colorectal Cancer
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Colorectal Cancer
Tumor Metabolism-Altering Regimen Achieves Clinical Benefit in Metastatic Pancreatic Cancer
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Pancreatic Cancer
CAR T-Cell Therapy Fills Unmet Needs in Leukemia and Lymphoma
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Immunotherapy
Genomic Markers of Response Improve Patient Selection for Immune Checkpoint Inhibitor Therapy
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Immunotherapy
CAR T-Cell Therapy Associated with Unique, Acute Adverse Events Requiring Vigilant Monitoring
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Immunotherapy
Immunotherapy Moving into Earlier Lines of Lung Cancer Therapy
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Lung Cancer
Personalizing Immunotherapy in NSCLC Using PD-L1 and Tumor Mutation Burden as Biomarkers
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Lung Cancer
Last modified: May 21, 2015